AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Kartagener Syndrome

Recent research efforts aimed at curing Kartagener Syndrome.

Last updated

Kartagener Syndrome

Overview

Kartagener syndrome is a form of primary ciliary dyskinesia (PCD), an inherited disorder in which microscopic, hair-like structures called motile cilia do not work normally. In the airways, cilia normally move mucus and germs out of the lungs; when they fail, people commonly develop lifelong wet cough, recurrent chest and sinus infections, ear disease and hearing problems, and progressive bronchiectasis (permanent widening and damage of airways). The name Kartagener syndrome is often used for PCD associated with situs inversus, in which internal organs are arranged as a mirror image of usual anatomy. Fertility can also be reduced because sperm tails and fallopian-tube cilia share related motility machinery. GeneReviews: Primary Ciliary Dyskinesia (ncbi.nlm.nih.gov)

Prognosis is highly variable: many people live into adulthood, but repeated infection and inflammation can lead to substantial lung damage, and some develop end-stage lung disease requiring transplantation. Current care is not curative. It focuses on daily airway-clearance techniques, exercise, vaccination, culture-guided antibiotics for infections, selected long-term macrolide antibiotics for frequent exacerbations, and management of sinus, ear, hearing, fertility, and congenital-heart issues when present. GeneReviews: Primary Ciliary Dyskinesia (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has shifted from treating the consequences of poor mucus clearance toward correcting the underlying genetic defect in airway cells. The field remains small but is becoming more trial-ready through international networks, better genetic diagnosis, patient-derived airway models, and the first human studies of inhaled messenger RNA (mRNA) replacement. A broadly applicable cure is not close: PCD/Kartagener syndrome is caused by pathogenic variants across more than 50 genes, and no approved therapy yet restores ciliary function. However, the DNAI1-targeted mRNA program has provided the first clinical test of a therapy designed to replace a missing ciliary protein rather than merely manage symptoms. GeneReviews: Primary Ciliary Dyskinesia PCD clinical-trial network (ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The leading disease-modifying approach is inhaled mRNA replacement. ReCode Therapeutics’ RCT1100 packages mRNA encoding the ciliary protein DNAI1 inside lipid nanoparticles—tiny fat-based delivery particles—and administers it by nebulizer. In 2022, researchers showed that aerosolized DNAI1 mRNA reached multiciliated airway cells in mice. In 2025, a follow-up study reported delivery and protein production in human airway-cell cultures and non-human primate airways, supporting the rationale for replacing DNAI1 in people whose PCD is caused by DNAI1 variants. This approach does not edit a person’s DNA; it aims to repeatedly supply a functional protein blueprint to airway cells. Inhaled DNAI1 mRNA in mice DNAI1 mRNA preclinical study (pubmed.ncbi.nlm.nih.gov)

This strategy reached first-in-human testing. A June 2026 conference report of RCT1100 Phase 1a single-dose and Phase 1b multiple-dose studies found that the treatment was generally tolerated at 3 mg and 5 mg doses in adults with DNAI1-related PCD, with no serious adverse events or grade 3-or-higher treatment-emergent adverse events reported. Crucially, the small Phase 1b study did not find a post-treatment improvement in measured outer-dynein-arm number, ciliary movement, or DNAI1 staining in bronchial samples. These early data therefore establish initial safety, not clinical efficacy or a cure. RCT1100 Phase 1a/1b results (academic.oup.com)

Other precision approaches remain preclinical. Readthrough therapy attempts to help cells ignore certain premature “stop” signals in mRNA so that a full-length ciliary protein can be made. In a 2021 patient-derived model of MCIDAS-related PCD, readthrough compounds, combined with inhibition of nonsense-mediated mRNA decay, restored basal-body formation in nasal epithelial cells in vitro. That is an important proof of principle, but it is relevant only to selected nonsense variants and has not yet become a clinical treatment. Readthrough screening in patient airway cells (discovery.ucl.ac.uk)

Gene editing and cell-based replacement are earlier still. CRISPR-Cas9 has been used to create precise PCD mutations in mice and to show that disease severity can depend on the specific variant and the affected tissue, information needed to design personalized genetic therapies. Investigators have also described corrected induced pluripotent stem-cell airway progenitors as a possible future route to restoring ciliated epithelium, but no gene-editing or cell-replacement therapy has entered human trials for Kartagener syndrome. Dnaaf5 CRISPR disease models Corrected iPSC airway-progenitor project (insight.jci.org)

Clinical Trials and Experimental Approaches

The principal root-cause clinical program is ReCode’s RCT1100. The completed RCT1100-101 study, registered as NCT05737485, evaluated single ascending inhaled doses in healthy volunteers and adults with DNAI1-related PCD. A subsequent multiple-dose study evaluated dosing three times weekly for 12 weeks, while a further open-label study, NCT06633757, is designed to measure changes in mucociliary clearance—the movement of inhaled radiotracer out of the lungs—through Week 12. These studies are limited to people with pathogenic DNAI1 variants, not all people with Kartagener syndrome. RCT1100-101 trial record RCT1100 mucociliary-clearance study RCT1100 Phase 1a/1b results (clinicaltrials.gov)

The most important recent non-genetic trial publication was CLEAN-PCD, a completed multinational Phase 2 crossover study of the epithelial sodium-channel blocker idrevloride, formerly VX-371, with or without hypertonic saline and ivacaftor. The trial enrolled 123 participants and reported that the idrevloride-plus-hypertonic-saline combination improved lung function relative to hypertonic saline alone. This is a potentially useful mucus-hydration strategy, but it does not restore defective cilia or correct the inherited cause of PCD. CLEAN-PCD trial record CLEAN-PCD Phase 2 publication (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers increasingly use nasal-brush samples from people with PCD to grow their own basal airway cells at an air–liquid interface, where the cells mature into mucus-producing and ciliated airway tissue. Miniaturized 96-well versions of these cultures retain many patient-specific ciliary defects and permit screening of many candidate drugs or RNA formulations. Researchers assess rescue using ciliary-protein staining, electron microscopy of ciliary structure, and high-speed video microscopy to measure beat frequency and pattern. Readthrough screening in patient airway cells GeneReviews: Primary Ciliary Dyskinesia (discovery.ucl.ac.uk)

For genetic therapies, the technical challenge is delivery to the right cells: existing ciliated cells, but also basal and club cells that can replenish the airway lining. The DNAI1 program uses inhaled, lung-directed lipid nanoparticles and measures whether mRNA reaches these target cells, produces protein, and improves mucociliary clearance. Complementary systems—including CRISPR-engineered mice, Xenopus ciliated epithelium, and genotype-specific patient cells—help define which mutations are most suitable for replacement, readthrough, or future editing strategies. DNAI1 mRNA preclinical study Dnaaf5 CRISPR disease models NIH PCD gene-discovery award (doi.org)

Leading Institutions and Funding

ReCode Therapeutics is the only organization with a reported human clinical program specifically intended to restore ciliary function in DNAI1-related PCD. Its studies involve clinical investigators and sites in the United Kingdom, United States, and Australia, including Royal Brompton Hospital, University Hospital Münster, the University of Dundee, and the University of Sydney. RCT1100 Phase 1a/1b results RCT1100-101 trial record (academic.oup.com)

Academic and charitable investment is expanding the pipeline beyond DNAI1. PCD Research and the Nucleic Acid Therapy Accelerator jointly awarded University College London a £250,000, two-year grant to develop CCDC39 mRNA therapy; CCDC39 is a clinically severe PCD subtype. In the United States, the NIH-funded Genetic Disorders of Mucociliary Clearance Consortium supports PCD research, while a Northwestern University NIH award for discovery and characterization of PCD genes totals $1,467,980 across fiscal years 2025 and 2026. European coordination is strengthened by the ERS BEAT-PCD collaboration and the PCD Clinical Trial Network, founded in 2020 to standardize studies and support recruitment across specialist sites. CCDC39 mRNA grant NIH PCD gene-discovery award BEAT-PCD PCD clinical-trial network (pcdresearch.org)

Strengths, Limitations, and Challenges

The major strength of current research is that it has crossed an important threshold: a treatment intended to replace a missing ciliary protein has been inhaled by people with PCD. mRNA also avoids permanently altering the genome and can be tailored to a specific defective gene. The early RCT1100 safety findings, patient-derived airway models, and coordinated trial networks create a credible foundation for testing whether restored protein expression can translate into improved mucus clearance, fewer infections, and preservation of lung function. RCT1100 Phase 1a/1b results PCD clinical-trial network (academic.oup.com)

The limitations are substantial. Kartagener syndrome is genetically diverse, so a DNAI1 medicine can help only the subgroup with DNAI1-related disease; 20%–30% of well-characterized PCD cases still lack an identifiable disease-causing variant. In the reported seven-person multiple-dose RCT1100 study, bronchial tests did not show structural or motion rescue after treatment, and there are not yet published data showing better symptoms, fewer exacerbations, or slowed bronchiectasis. Repeated inhaled dosing, effective delivery through mucus and inflamed airways, durable uptake by the right airway-cell populations, pediatric testing, manufacturing cost, and equitable access remain unresolved challenges. GeneReviews: Primary Ciliary Dyskinesia RCT1100 Phase 1a/1b results DNAI1 mRNA preclinical study (ncbi.nlm.nih.gov)

Outlook and Future Directions

As of August 8, 2026, Kartagener syndrome does not have a curative therapy, but the field has moved from theoretical gene therapy toward early human testing of inhaled mRNA replacement. The next decisive milestones are reproducible evidence that RCT1100 improves mucociliary clearance and meaningful clinical outcomes, longer-term safety data with repeat dosing, and extension of the platform to additional high-impact genes such as CCDC39. A true cure will likely require a family of gene- and variant-specific treatments rather than one universal medicine; for now, the realistic near-term objective is a disease-modifying treatment that restores enough airway ciliary function to prevent infections and irreversible lung damage. RCT1100 mucociliary-clearance study CCDC39 mRNA grant GeneReviews: Primary Ciliary Dyskinesia (clinicaltrials.gov)

References

Don't see your disease? Request a report